Kamada LTD revenue

Kamada LTD's revenue was $180m in fiscal 2025, up 12.1% on the year before. Since fiscal 2015 ($69.9m) it has grown at a compound 9.9% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Kamada LTD: revenue history, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	70	77	103	114	127	133	104	129	143	161	180
Growth on the year before	—	+10.9%	+32.7%	+11.3%	+11.1%	+4.8%	−22.2%	+24.8%	+10.2%	+12.9%	+12.1%
Gross profit	15	21	32	41	50	48	30	47	55	70	76
Gross margin	22.0%	27.6%	31.2%	36.2%	39.1%	35.7%	29.3%	36.1%	38.9%	43.5%	42.3%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Kamada LTD	$180m	12.1%	—
Cronos Group Inc.	$179m	37.5%	30.3%
Biote Corp.	$184m	-7.8%	0.5%
Amarin Corp plc\uk	$176m	-22.3%	-18.3%
Organigram Global Inc.	$185m	57.8%	—
Heron Therapeutics, Inc.	$151m	1.0%	8.6%

Compare with peers

Head to head: CRON vs KMDA BTMD vs KMDA AMRN vs KMDA KMDA vs OGI

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Kamada LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kamada LTD.